Why a $28 Cash Offer Lost to a $25 Takeover

Surgery Partners raised the price of its own buyout on Monday, and the higher offer still lost. Two weeks after agreeing to be taken private, the surgical-facility operator announced an amended merger agreement with HealthSpan Partners, lifting the per-share consideration to $25.00 in cash from the $23.50 originally agreed on October 26. The raise came only because an unnamed third party had surfaced with a bid of $28.00 per share, more than the amended deal pays. The special committee looked at both and chose the smaller number.

The committee's three reasons

The unsolicited proposal arrived on November 3 and was updated on November 8, non-binding throughout, and it proposed cash for all outstanding shares at $28.00. The committee, composed entirely of independent and disinterested directors, unanimously concluded it did not constitute a Superior Proposal, and the release lays out why in three parts.

First, the committee judged that a deal with the third party would be expected to take materially longer to close than the amended HealthSpan agreement, or may not close at all, which in its view reduces the value of the proposed consideration. Second, it weighed the regulatory risk and complexity of a transaction with the unnamed bidder against a transaction with HealthSpan, a contractual affiliate and supporting organization of Bon Secours Mercy Health. Third, the third party did not provide the contractual and other protections the committee sought.

Those protections matter more after the amendment itself. The revised agreement adds a Ticking Fee: if stockholders approve the merger but closing has not occurred by March 1, 2027, shareholders other than Bain Capital affiliates begin receiving monthly cash payments, in equal installments in arrears, at a rate of 10% per annum on the $25.00 consideration. If approval comes before March 1 and closing drags to the outside date of October 23, 2027, those holders collect up to $1.61 per share in fees, bringing maximum per-share consideration to $26.61 and enterprise value to as much as approximately $6.0 billion.

Read together, the mechanics are the argument. A paper bid of $28.00 with no signed protections is worth less, in the committee's math, than a contracted $25.00 that pays sellers 10% a year for waiting. The committee treated the higher number as unpriced against delay, and attached its own delay insurance to the lower one instead.

What Bain's rollover means for the vote

The largest holder is not taking cash. Bain Capital affiliates, holders of approximately 39% of outstanding shares, will receive no merger consideration at all, including none of the Ticking Fee. They roll their shares into equity of the acquiring entity and remain a significant partner of HealthSpan Partners after closing. Bain has already signed a voting and support agreement covering all of its shares, and that agreement remains in place under the amended terms.

The structure explains the deal's stability and its tension at once. A 39% holder voting in favor means the stockholder vote starts with nearly two-fifths of the shares already committed, which is the kind of closing certainty the committee valued over the $28.00 bid. It also means the party whose economics changed least in the amendment, since Bain collects neither the higher cash price nor the ticking fee, is the party whose continued partnership the transaction depends on. Bain's upside is now the rolled equity, not the exit.

What the stock's discount says

The market has not bought the guarantee. Surgery Partners closed at $23.20 on November 6, the last trading day before the amended terms were announced. That is $1.80 below the amended price, $3.41 below the $26.61 maximum, and $4.80 below the rejected bid. The gap prices the same risks the committee named: regulatory approval, the stockholder vote and the conditionality of a first-quarter 2027 close, a timeline the parties reaffirmed alongside the amendment, with HealthSpan financing the purchase through cash on hand and committed new debt for which Jefferies is sole initial underwriter and exclusive financial advisor.

Surgery Partners operates more than 200 short-stay surgical locations across 30 states, from ambulatory surgery centers to surgical hospitals, and the asset drew a competing bidder within two weeks of signing. What Monday's decision establishes is the price of certainty itself: a contracted $25.00 that can grow to $26.61 with waiting beat an uncontracted $28.00, and the stock trading below both numbers says investors still want to see the calendar confirm it.